Survey results suggest that chronic myeloid leukaemia (CML) patients using tyrosine kinase inhibitor (TKI) therapy have good adherence to treatment but might benefit from counselling regarding their ...
Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) has announced the publication 1 in the Journal of Clinical Pathology of a study conducted in collaboration with the Memorial ...
Real world evidence on treatment efficacy and safety of tyrosine kinase inhibitors in patients with chronic myeloid leukemia.
Chronic myeloid leukemia (CML) is a type of blood cancer that arises from malignant changes in blood-forming cells of the bone marrow. It mainly occurs in older individuals and represents about 20% of ...
64% MMR achievement by 24 weeks across all efficacy evaluable patients The ASH presentation will be made available on the Terns Pharmaceuticals website simultaneously with the oral presentation by ...
Hosted on MSN
Living with chronic myeloid leukaemia: Najha’s story
KUALA LUMPUR: For many, chronic myeloid leukaemia (CML) is an unfamiliar term. It is a type of blood cancer that begins in the bone marrow and affects white blood cells. While not as common as other ...
Gleevec, a cancer drug first approved for sale in 2001, has dramatically changed the lives of people with chronic myeloid leukemia. This form of cancer was once regarded as very difficult to combat, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results